GlycoMimetics Inc. (NASDAQ:GLYC)’s share price was up 5.9% during trading on Friday . The stock traded as high as $7.82 and last traded at $7.68, with a volume of 59,355 shares changing hands. The stock had previously closed at $7.25.

Several equities analysts recently commented on GLYC shares. Zacks Investment Research upgraded shares of GlycoMimetics from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a report on Tuesday, May 10th. Canaccord Genuity reiterated a “buy” rating and set a $12.00 price target on shares of GlycoMimetics in a report on Wednesday, May 4th.

The company has a 50-day moving average price of $7.45 and a 200 day moving average price of $6.11. The company’s market cap is $152.28 million.

GlycoMimetics (NASDAQ:GLYC) last issued its quarterly earnings results on Wednesday, May 4th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.07. Analysts anticipate that GlycoMimetics Inc. will post ($1.82) earnings per share for the current fiscal year.

In related news, CMO Helen M. Thackray sold 22,000 shares of GlycoMimetics stock in a transaction that occurred on Wednesday, July 6th. The shares were sold at an average price of $7.00, for a total value of $154,000.00. Following the completion of the transaction, the chief marketing officer now owns 179,547 shares in the company, valued at $1,256,829. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

GlycoMimetics, Inc is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.